Global Ophthalmology Drugs Market to 2022 – Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period : Ken Research

New Delhi, September 15, 2016: Overall, there are 734 products in active development in the ophthalmology therapy area, making it the eighth-largest therapy area pipeline.

Ophthalmology has more active pipeline products than dermatology, hematology or genetic disorders, which reflects how active this disease cluster is in terms of product development, and that drug developers are willing to invest significant amounts into this area, given the potential of high commercial reward. However, the ophthalmology pipeline is smaller than the immunology, metabolic disorders and cardiology pipelines. The oncology pipeline is the largest, with vascular endothelial growth factor (VEGF) therapies crossing over into the ophthalmology pipeline.

There are some promising products in late-stage development within the ophthalmology disease area. The promising drugs Fovista, SPK-RPE65, lampalizumab and Rhopressa all have different molecule types: aptamer, gene therapy, monoclonal Antibody (mAb) and small molecule, respectively.

Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

Global revenues for the ophthalmology market are forecast to grow at a compound annual growth rate of 9.48%, from USD 13.7 billion in 2015 to USD 26 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?

Which products will contribute to market growth most significantly, and which will achieve blockbuster status?

Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

New Companies to Enter the Market

A range of companies are actively involved in the development or marketing of ophthalmology products. These include a number of publically traded companies, as well as a few top-20 pharmaceutical companies (by overall revenues), privately-held enterprises, and government and academic institutions.

The introduction of smaller specialized companies into the market suggests a shift away from the top companies within the ophthalmology landscape. Four new companies (Ophthotech, Spark Therapeutics, Aerie Pharmaceuticals and Eleven Biotherapeutics) will enter the market during the forecast period, and some of them are anticipated to become key players within this timeframe. The key companies in the market, including Bayer and Novartis, are expected to maintain their strong positions. However, the new player Ophthotech is forecast to overtake Roche in terms of total revenue created within ophthalmology.

Corporate Comm India(CCI Newswire)